MedTrace Logo

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

NCT06554626 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-08-15

No results posted yet for this study

Summary

Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival of B-ALL patients has significantly improved. In this study，we propose a treatment approach that combines Blinatumomab and Venetoclax sequenced with Inotuzumab Ozogamicin in B-ALL adults. Our study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.

Conditions

  • Precursor B-Cell Lymphoblastic Leukemia

Interventions

DRUG

Dexamethasone

Glucocorticoids

DRUG

Blinatumomab

Bi-specific anti CD19/CD3 antibody

DRUG

Venetoclax

BCL-2 inhibotor

DRUG

Inotuzumab ozogamicin

a humanized monoclonal antibody-drug conjugate targeting CD22

DRUG

Methotrexate

antifolate antineoplastic drug

DRUG

Pegaspargase

antitumor drug

DRUG

Cytarabine

Pyrimidine, antimetabolites

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2026-08-01
Completion
2027-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554626 on ClinicalTrials.gov